Biotech Values

[ghmm]

HGSI:

I don't follow HGSI too closely. I had thought that Albuferon was not as efficacious as the PEG's just better dosing/compliance. Is this release misleading?

3:19AM Human Genome Sciences reports positive interim results of Phase 2b trial of Albuferon (HGSI) 11.51 : Co reports results at Week 12 following the completion of therapy in a Phase 2b clinical trial of Albuferon in combination with ribavirin in patients with genotype 1 chronic hepatitis C who are naive to interferon alpha-based treatment regimens. The interim results of the Phase 2b trial demonstrated that Albuferon provided at least comparable efficacy vs. Pegasys. The treatment group receiving Albuferon 900-mcg doses every two weeks achieved a 59% rate of sustained virologic response at 12 weeks following completion of therapy, vs. 54% for Pegasys administered once every week.